Phase 2 Small Lymphocytic Lymphoma Clinical Trials
44 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 44 trials
Recruiting
Phase 2
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center20 enrolled1 locationNCT07194980
Recruiting
Phase 2
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI)20 enrolled3 locationsNCT07061951
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06839053
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled20 locationsNCT07221500
Recruiting
Phase 2
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
M.D. Anderson Cancer Center168 enrolled1 locationNCT04169737
Recruiting
Phase 2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Massachusetts General Hospital40 enrolled3 locationsNCT04560322
Recruiting
Phase 2
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled73 locationsNCT05963074
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 2
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
University of Utah61 enrolled1 locationNCT05183854
Recruiting
Phase 2
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ascentage Pharma Group Inc.75 enrolled11 locationsNCT05147467
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 2
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter Syndrome
Mayo Clinic27 enrolled3 locationsNCT05388006
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 2
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
City of Hope Medical Center33 enrolled7 locationsNCT07218510
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 2
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center52 enrolled1 locationNCT05336812
Recruiting
Phase 2
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Kerry Rogers30 enrolled1 locationNCT06466122